| Literature DB >> 22457606 |
Andresa Aparecida Berretta1, Andresa Piacezzi Nascimento, Paula Carolina Pires Bueno, Mirela Mara de Oliveira Lima Leite Vaz, Juliana Maldonado Marchetti.
Abstract
The aim of this study was to develop a formulation, containing the propolis standardized extract (EPP-AF(®)), which can assist in the healing of skin lesions. To achieve this objective the antimicrobial activity and chemical composition of the propolis extract was determined. The final product was subjected to in vitro and in vivo pre-clinical evaluation. The broth macrodilution method was used to determine the antimicrobial activity of the extracts and formulations against the microorganisms most commonly found in burns, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus and Staphylococcus epidermidis. Wistar rats with puncture wounded skin were used to evaluate the wound healing properties of propolis. The results of chemical and biological characterization demonstrated the batch-to-batch reproducibility of the standardized extract which is an unprecedented result. The antimicrobial and wound healing activity of the pharmaceutical studied showed the best results when samples contain 3.6% propolis, suggesting that this is the most promising composition.Entities:
Keywords: EPP-AF®; antimicrobial activity; pharmaceutics; propolis; reproducibility; wound healing
Mesh:
Substances:
Year: 2012 PMID: 22457606 PMCID: PMC3314192 DOI: 10.7150/ijbs.3641
Source DB: PubMed Journal: Int J Biol Sci ISSN: 1449-2288 Impact factor: 6.580
Chemical characterization of the standardized propolis extracts (EPP-AF®) used in this study (n=4) (mg/g).
| Compounds | Standardized Propolis Extract | ||
|---|---|---|---|
| Aa | Bb | Cc | |
| caffeic acid | 0.299 ± 0.024 | 0.336 ± 0.027 | 0.288 ± 0.009 |
| 1.561 ± 0.090 | 1.524 ± 0.108 | 1.486 ± 0.052 | |
| 0.091 ± 0.055 | 0.167 ± 0.001 | 0.153 ± 0.009 | |
| aromadendrin | 1.020 ± 0.168 | 0.993 ± 0.075 | 1.125 ± 0.022 |
| isosakuranetin | 2.261 ± 0.135 | 2.256 ± 0.144 | 2.265 ± 0.084 |
| artepilin C | 7.553 ± 1.497 | 8.533 ± 0.522 | 6.962 ± 0.261 |
a Batch 010/08 of EPP-AF®.
b Batch 1440110 of EPP-AF®.
c Batch 1400410 of EPP-AF®.
Figure 1Chromatographic profile of (a) Propolis Standardized Extract (EPP-AF®) Batch 1440110 ; (b) Batch 1400410 and (c) Batch 010/08. Chromatographic profile includes the compounds: 1. Caffeic acid (around 15 min.); 2. p-coumaric acid (around 20 min.); 3. trans-cinnamic acid (around 36 min.), 4. aromadendrin (38 min.) 5. isosakuretin (around 48 min.) and 6.Artepillin C (around 61 min.). The chromatograms were plotted at 275 nm, using the RP-HPLC, C18 (Shim-pack, CLC-ODS (M), 25 cm x 4.6) column and gradient elution with methanol and acidic water (formic acid pH=2.7).
Minimum bactericidal concentration (MBC) of the three batches of standardized propolis extract (EPP-AF® - A, B and C) (n=3).
| Microorganism | MBC (mg/mL) | ||
|---|---|---|---|
| Aa | Bb | Cc | |
| 14.05 (0.00) | 13.93 (0.00) | 14.00 (0.00) | |
| 14.05 (0.00) | 13.93 (0.00) | 14.00 (0.00) | |
| 14.05 (0.00) | 13.93 (0.00) | 14.00 (0.00) | |
| 7.02 (0.00) | 6.96 (0.00) | 7.00 (0.00) | |
| 3.51 (0.00) | 3.48 (0.00) | 3.50 (0.00) | |
| 7.02 (0.00) | 6.96 (0.00) | 7.00 (0.00) |
a Batch 10/08 of EPP-AF® (11.24% w/v dry propolis extract).
b Batch 1440110 of EPP-AF® (11.15% w/v dry propolis extract).
c Batch 1400410 of EPP-AF® (11.20% w/v dry propolis extract).
Figure 2Photograph showing the healing process of the control group (A) and the group treated with gel in the absence of propolis (B and C) after 3 days of treatment. Slices of 6 μm were obtained and stained with Masson´s trichromic. a) Lesions treated with saline (control). Start of the healing process (100x magnification); b) Lesions treated with gel without propolis. Start of the healing process (100x magnification); c) Lesions treated with gel without propolis. Cream leukocitary cells (arrow) observed just below the initial clot (*) (400X magnification).
Figure 3Photograph showing the healing process after three days of treatment with the gel containing 1.2% of dry extract of propolis. a) Lesions treated with gel containing standardized extract of propolis (1.2%) in the subcutaneous tissue. The reorganization of epithelial cells (c) and increased collagen fibers were observed just below the initial clot (*). Slices of 6 μm were obtained and stained with Masson´s trichromic (100x magnification); b) lesions treated with gel containing standardized extract of propolis (1.2%). There are a large number of fibroblasts synthesizing collagen (arrow). Slices of 6 μm were obtained and stained with Masson´s trichromic (400X magnification).
Figure 4Photograph showing the healing process after three days of treatment with the gels containing either 2.4% or 3.6% propolis. Slices of 6 μm were obtained and stained with Masson´s trichromic. a) Lesions treated with the 2.4% propolis gel. Closing of the lesion in the epithelial layer (1) and subcutaneously (2) there is a large number of fibroblasts synthesizing collagen (arrow) (100x magnification); b) Lesion treated with the 2.4% propolis gel. Subcutaneously (2) there is an increase of collagen fibers and a large number of cells undergoing mitosis (arrow) (400X magnification); c) Lesions treated with the 3.6% propolis gel. Wound area completely rebuilt, the epithelium (1) is already presented in several layers forming the corneal region. Subcutaneously (2) thicker collagen fibers (arrow) were observed (400X magnification).
Minimum inhibitory concentration (MIC) of the formulations (samples 1, 2 and 3) containing the batches A, B and C of standardized propolis extract (EPP-AF®) (n=3).
| Microorganism | MIC (mg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sample 1a | Sample 2b | Sample 3c | |||||||
| Ad | Be | Cf | A | B | C | A | B | C | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 18 | 18 | 18 | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 18 | 18 | 18 | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 18 | 18 | 18 | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 9 | 9 | 9 | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 9 | 9 | 9 | |
| > 6 | > 6 | > 6 | > 12 | > 12 | > 12 | 9 | 9 | 9 | |
a 1.2% (w/v) propolis dry extract; b 2.4% (w/v) propolis dry extract; c 3.6% (w/v) propolis dry extract; d Batch 010/08 of EPP-AF®; e Batch 1440110 of EPP-AF®; f Batch 1400410 of EPP-AF®.